Fenwick Represents Stoke Therapeutics Inc. in $163M Initial Public Offering

Fenwick & West represents Stoke Therapeutics Inc. (STOK), a biotechnology firm developing therapies for genetic diseases, in its initial public offering of 6.7 million shares of its common stock at a price to the public of $18 per share.

Stoke's underwriters are J.P. Morgan Securities LLC, Cowen and Co. LLC, Credit Suisse Securities (USA) LLC and Canaccord Genuity LLC.

The Fenwick transaction team included corporate lawyers: Robert Freedman, Effie Toshav, Alan Smith, Julia Forbess, Michael Shaw, Derrick Chapman and Joshua Fuller; executive compensation and employee benefits lawyers: Elizabeth Gartland and Laura McIntyre.